$0.28 EPS Expected for Vertex Pharmaceuticals Incorporated (VRTX)

January 4, 2018 – By Louis Casey

Investors sentiment increased to 1.62 in 2017 Q3. Its up 0.11, from 1.51 in 2017Q2. It increased, as 32 investors sold Vertex Pharmaceuticals Incorporated shares while 151 reduced holdings. 79 funds opened positions while 217 raised stakes. 231.42 million shares or 0.04% more from 231.33 million shares in 2017Q2 were reported.
1,050 are held by First Interstate State Bank. Old Mutual Global Invsts (Uk) Limited holds 1.20M shares. Cullen Frost Bankers invested in 0.01% or 2,347 shares. Warren Averett Asset Mgmt Limited Liability Company, Alabama-based fund reported 2,217 shares. Arrowstreet Partnership invested in 0.26% or 632,934 shares. Mark Sheptoff Financial Planning Ltd Limited Liability Company has 11,415 shares for 1.17% of their portfolio. Neuberger Berman Grp Inc Lc reported 0.04% stake. First Personal Fincl Serv has invested 0% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Proshare Advsrs Ltd Liability holds 217,305 shares. Sg Americas Limited Liability Company accumulated 0.02% or 15,282 shares. C M Bidwell Ltd owns 10 shares. Sun Life Fincl stated it has 0.03% of its portfolio in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Nippon Life Ins Com holds 0.03% of its portfolio in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) for 10,032 shares. Jag Cap Limited Liability Corporation, a Missouri-based fund reported 33,583 shares. Hirtle Callaghan And Company Ltd Llc stated it has 112 shares.

Since July 31, 2017, it had 0 insider buys, and 20 selling transactions for $62.07 million activity. Another trade for 5,390 shares valued at $830,960 was made by Chodakewitz Jeffrey on Wednesday, August 2. On Thursday, August 31 ALTSHULER DAVID sold $287,360 worth of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) or 1,796 shares. SMITH IAN F had sold 75,000 shares worth $10.88M. $131,571 worth of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) shares were sold by Silva Paul M. LEIDEN JEFFREY M sold $17.67M worth of stock or 125,000 shares. Another trade for 2,330 shares valued at $362,828 was sold by Parini Michael.

Analysts expect Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) to report $0.28 EPS on January, 24.They anticipate $0.15 EPS change or 115.38 % from last quarter’s $0.13 EPS. VRTX’s profit would be $70.81M giving it 136.92 P/E if the $0.28 EPS is correct. After having $0.24 EPS previously, Vertex Pharmaceuticals Incorporated’s analysts see 16.67 % EPS growth. The stock increased 0.88% or $1.34 during the last trading session, reaching $153.35. About 992,991 shares traded. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has risen 45.69% since January 4, 2017 and is uptrending. It has outperformed by 28.99% the S&P500.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Ratings Coverage

Among 27 analysts covering Vertex Pharmaceuticals (NASDAQ:VRTX), 23 have Buy rating, 0 Sell and 4 Hold. Therefore 85% are positive. Vertex Pharmaceuticals had 80 analyst reports since July 31, 2015 according to SRatingsIntel. RBC Capital Markets maintained the shares of VRTX in report on Thursday, April 28 with “Outperform” rating. The firm earned “Neutral” rating on Monday, October 24 by H.C. Wainwright. As per Wednesday, July 19, the company rating was upgraded by Raymond James. The firm has “Market Perform” rating given on Tuesday, November 1 by William Blair. As per Thursday, February 11, the company rating was initiated by Oppenheimer. Piper Jaffray maintained the shares of VRTX in report on Thursday, October 26 with “Buy” rating. As per Wednesday, July 19, the company rating was maintained by H.C. Wainwright. On Thursday, April 28 the stock rating was downgraded by Goldman Sachs to “Neutral”. The firm has “Outperform” rating given on Wednesday, July 19 by Cowen & Co. The stock of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) earned “Buy” rating by Jefferies on Thursday, October 26.

Vertex Pharmaceuticals Incorporated discovers, develops, makes, and commercializes medicines for serious diseases. The company has market cap of $38.78 billion. The firm focuses on developing and commercializing therapies for the treatment of cystic fibrosis and advancing its research and development programs. It has a 197.62 P/E ratio. It markets ORKAMBI (lumacaftor in combination with ivacaftor) for the treatment of patients with CF 12 years of age and older who have two copies (homozygous) of the F508del mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene; and KALYDECO (ivacaftor) for the treatment of patients with CF 2 years of age and older who have the G551D mutation or other specified mutations in their CFTR gene.